Longitudinal associations between eGFRdiff, other kidney function measures and global cognitive trajectories based on inverse probability–weighted samples.
| . | Model 1 . | Model 2 . | Model 3 . | |||
|---|---|---|---|---|---|---|
| Associations . | OR (95% CI) . | P-value . | OR (95% CI) . | P-value . | OR (95% CI) . | P-value . |
| Difference between eGFRcys and eGFRcr | ||||||
| Continuous eGRFdiff (ml/min/1.73 m2) | ||||||
| Per SD increase | 0.894 (0.867–0.922) | <0.001 | 0.904 (0.872–0.937) | <0.001 | 0.909 (0.877–0.942) | <0.001 |
| Per SD increase (adjusted for eGFRcr) | 0.894 (0.866–0.923) | <0.001 | 0.885 (0.852–0.919) | <0.001 | 0.889 (0.856–0.923) | <0.001 |
| Categorical eGRFdiff (ml/min/1.73 m2) | ||||||
| Midrange (eGFRdiff −15–15) | Reference | Reference | Reference | |||
| Negative (eGFRdiff <−15) | 1.216 (1.144–1.293) | <0.001 | 1.216 (1.133–1.305) | <0.001 | 1.204 (1.121–1.292) | <0.001 |
| Positive (eGFRdiff ≥15) | 0.858 (0.745–0.988) | 0.035 | 0.933 (0.792–1.099) | 0.411 | 0.928 (0.787–1.093) | 0.373 |
| Cystatin C and creatinine-based kidney function measures | ||||||
| Continuous serum cystatin C (mg/l) | ||||||
| Per SD increase | 1.074 (1.040–1.110) | <0.001 | 1.121 (1.080–1.163) | <0.001 | 1.114 (1.074–1.156) | <0.001 |
| Per SD increase (adjusted for creatinine) | 1.120 (1.079–1.164) | <0.001 | 1.145 (1.099–1.194) | <0.001 | 1.138 (1.093–1.187) | <0.001 |
| Continuous eGFRcys (ml/min/1.73 m2) | ||||||
| Per SD increase | 0.913 (0.881–0.945) | <0.001 | 0.872 (0.837–0.908) | <0.001 | 0.874 (0.840–0.910) | <0.001 |
| Per SD increase (adjusted for eGFRcr) | 0.873 (0.840–0.908) | <0.001 | 0.862 (0.824–0.902) | <0.001 | 0.868 (0.829–0.908) | <0.001 |
| Continuous serum creatinine (mg/dl) | ||||||
| Per SD increase | 0.946 (0.911–0.983) | 0.004 | 1.007 (0.965–1.051) | 0.749 | 1.024 (0.985–1.065) | 0.235 |
| Per SD increase (adjusted for cystatin C) | 0.896 (0.859–0.934) | <0.001 | 0.942 (0.898–0.988) | 0.013 | 0.956 (0.914–1.001) | 0.054 |
| Continuous eGFRcr (ml/min/1.73 m2) | ||||||
| Per SD increase | 1.067 (1.030–1.106) | <0.001 | 0.975 (0.935–1.016) | 0.228 | 0.969 (0.930–1.010) | 0.141 |
| Per SD increase (adjusted for eGFRcys) | 1.102 (1.060–1.146) | <0.001 | 1.024 (0.978–1.072) | 0.310 | 1.017 (0.972–1.065) | 0.466 |
| Continuous eGRFcys-cr (ml/min/1.73 m2) | ||||||
| Per SD increase | 0.979 (0.944–1.015) | 0.240 | 0.897 (0.86–0.935) | <0.001 | 0.896 (0.859–0.934) | <0.001 |
| Per SD increase (adjusted for eGFRcr) | 0.854 (0.809–0.901) | <0.001 | 0.819 (0.769–0.871) | <0.001 | 0.824 (0.774–0.878) | <0.001 |
| Per SD increase (adjusted for eGFRcys) | 1.333 (1.216–1.462) | <0.001 | 1.052 (0.945–1.171) | 0.356 | 1.035 (0.930–1.153) | 0.527 |
| . | Model 1 . | Model 2 . | Model 3 . | |||
|---|---|---|---|---|---|---|
| Associations . | OR (95% CI) . | P-value . | OR (95% CI) . | P-value . | OR (95% CI) . | P-value . |
| Difference between eGFRcys and eGFRcr | ||||||
| Continuous eGRFdiff (ml/min/1.73 m2) | ||||||
| Per SD increase | 0.894 (0.867–0.922) | <0.001 | 0.904 (0.872–0.937) | <0.001 | 0.909 (0.877–0.942) | <0.001 |
| Per SD increase (adjusted for eGFRcr) | 0.894 (0.866–0.923) | <0.001 | 0.885 (0.852–0.919) | <0.001 | 0.889 (0.856–0.923) | <0.001 |
| Categorical eGRFdiff (ml/min/1.73 m2) | ||||||
| Midrange (eGFRdiff −15–15) | Reference | Reference | Reference | |||
| Negative (eGFRdiff <−15) | 1.216 (1.144–1.293) | <0.001 | 1.216 (1.133–1.305) | <0.001 | 1.204 (1.121–1.292) | <0.001 |
| Positive (eGFRdiff ≥15) | 0.858 (0.745–0.988) | 0.035 | 0.933 (0.792–1.099) | 0.411 | 0.928 (0.787–1.093) | 0.373 |
| Cystatin C and creatinine-based kidney function measures | ||||||
| Continuous serum cystatin C (mg/l) | ||||||
| Per SD increase | 1.074 (1.040–1.110) | <0.001 | 1.121 (1.080–1.163) | <0.001 | 1.114 (1.074–1.156) | <0.001 |
| Per SD increase (adjusted for creatinine) | 1.120 (1.079–1.164) | <0.001 | 1.145 (1.099–1.194) | <0.001 | 1.138 (1.093–1.187) | <0.001 |
| Continuous eGFRcys (ml/min/1.73 m2) | ||||||
| Per SD increase | 0.913 (0.881–0.945) | <0.001 | 0.872 (0.837–0.908) | <0.001 | 0.874 (0.840–0.910) | <0.001 |
| Per SD increase (adjusted for eGFRcr) | 0.873 (0.840–0.908) | <0.001 | 0.862 (0.824–0.902) | <0.001 | 0.868 (0.829–0.908) | <0.001 |
| Continuous serum creatinine (mg/dl) | ||||||
| Per SD increase | 0.946 (0.911–0.983) | 0.004 | 1.007 (0.965–1.051) | 0.749 | 1.024 (0.985–1.065) | 0.235 |
| Per SD increase (adjusted for cystatin C) | 0.896 (0.859–0.934) | <0.001 | 0.942 (0.898–0.988) | 0.013 | 0.956 (0.914–1.001) | 0.054 |
| Continuous eGFRcr (ml/min/1.73 m2) | ||||||
| Per SD increase | 1.067 (1.030–1.106) | <0.001 | 0.975 (0.935–1.016) | 0.228 | 0.969 (0.930–1.010) | 0.141 |
| Per SD increase (adjusted for eGFRcys) | 1.102 (1.060–1.146) | <0.001 | 1.024 (0.978–1.072) | 0.310 | 1.017 (0.972–1.065) | 0.466 |
| Continuous eGRFcys-cr (ml/min/1.73 m2) | ||||||
| Per SD increase | 0.979 (0.944–1.015) | 0.240 | 0.897 (0.86–0.935) | <0.001 | 0.896 (0.859–0.934) | <0.001 |
| Per SD increase (adjusted for eGFRcr) | 0.854 (0.809–0.901) | <0.001 | 0.819 (0.769–0.871) | <0.001 | 0.824 (0.774–0.878) | <0.001 |
| Per SD increase (adjusted for eGFRcys) | 1.333 (1.216–1.462) | <0.001 | 1.052 (0.945–1.171) | 0.356 | 1.035 (0.930–1.153) | 0.527 |
Model 1: adjusted for age, gender, marital status, education level, residence, smoking status, drinking status, depressive symptoms, BMI, restriction on ADL, hypertension, diabetes, stroke, heart disease, chronic lung disease, cancer, total cholesterol, hs-CRP, use of antihypertensive agents and medication history of kidney disease. Model 2: further adjusted for global cognitive scores at baseline in 2011. Model 3: further adjusted for muscle strength assessed by grip strength (normalized by body weight).
Significant values in bold.
Longitudinal associations between eGFRdiff, other kidney function measures and global cognitive trajectories based on inverse probability–weighted samples.
| . | Model 1 . | Model 2 . | Model 3 . | |||
|---|---|---|---|---|---|---|
| Associations . | OR (95% CI) . | P-value . | OR (95% CI) . | P-value . | OR (95% CI) . | P-value . |
| Difference between eGFRcys and eGFRcr | ||||||
| Continuous eGRFdiff (ml/min/1.73 m2) | ||||||
| Per SD increase | 0.894 (0.867–0.922) | <0.001 | 0.904 (0.872–0.937) | <0.001 | 0.909 (0.877–0.942) | <0.001 |
| Per SD increase (adjusted for eGFRcr) | 0.894 (0.866–0.923) | <0.001 | 0.885 (0.852–0.919) | <0.001 | 0.889 (0.856–0.923) | <0.001 |
| Categorical eGRFdiff (ml/min/1.73 m2) | ||||||
| Midrange (eGFRdiff −15–15) | Reference | Reference | Reference | |||
| Negative (eGFRdiff <−15) | 1.216 (1.144–1.293) | <0.001 | 1.216 (1.133–1.305) | <0.001 | 1.204 (1.121–1.292) | <0.001 |
| Positive (eGFRdiff ≥15) | 0.858 (0.745–0.988) | 0.035 | 0.933 (0.792–1.099) | 0.411 | 0.928 (0.787–1.093) | 0.373 |
| Cystatin C and creatinine-based kidney function measures | ||||||
| Continuous serum cystatin C (mg/l) | ||||||
| Per SD increase | 1.074 (1.040–1.110) | <0.001 | 1.121 (1.080–1.163) | <0.001 | 1.114 (1.074–1.156) | <0.001 |
| Per SD increase (adjusted for creatinine) | 1.120 (1.079–1.164) | <0.001 | 1.145 (1.099–1.194) | <0.001 | 1.138 (1.093–1.187) | <0.001 |
| Continuous eGFRcys (ml/min/1.73 m2) | ||||||
| Per SD increase | 0.913 (0.881–0.945) | <0.001 | 0.872 (0.837–0.908) | <0.001 | 0.874 (0.840–0.910) | <0.001 |
| Per SD increase (adjusted for eGFRcr) | 0.873 (0.840–0.908) | <0.001 | 0.862 (0.824–0.902) | <0.001 | 0.868 (0.829–0.908) | <0.001 |
| Continuous serum creatinine (mg/dl) | ||||||
| Per SD increase | 0.946 (0.911–0.983) | 0.004 | 1.007 (0.965–1.051) | 0.749 | 1.024 (0.985–1.065) | 0.235 |
| Per SD increase (adjusted for cystatin C) | 0.896 (0.859–0.934) | <0.001 | 0.942 (0.898–0.988) | 0.013 | 0.956 (0.914–1.001) | 0.054 |
| Continuous eGFRcr (ml/min/1.73 m2) | ||||||
| Per SD increase | 1.067 (1.030–1.106) | <0.001 | 0.975 (0.935–1.016) | 0.228 | 0.969 (0.930–1.010) | 0.141 |
| Per SD increase (adjusted for eGFRcys) | 1.102 (1.060–1.146) | <0.001 | 1.024 (0.978–1.072) | 0.310 | 1.017 (0.972–1.065) | 0.466 |
| Continuous eGRFcys-cr (ml/min/1.73 m2) | ||||||
| Per SD increase | 0.979 (0.944–1.015) | 0.240 | 0.897 (0.86–0.935) | <0.001 | 0.896 (0.859–0.934) | <0.001 |
| Per SD increase (adjusted for eGFRcr) | 0.854 (0.809–0.901) | <0.001 | 0.819 (0.769–0.871) | <0.001 | 0.824 (0.774–0.878) | <0.001 |
| Per SD increase (adjusted for eGFRcys) | 1.333 (1.216–1.462) | <0.001 | 1.052 (0.945–1.171) | 0.356 | 1.035 (0.930–1.153) | 0.527 |
| . | Model 1 . | Model 2 . | Model 3 . | |||
|---|---|---|---|---|---|---|
| Associations . | OR (95% CI) . | P-value . | OR (95% CI) . | P-value . | OR (95% CI) . | P-value . |
| Difference between eGFRcys and eGFRcr | ||||||
| Continuous eGRFdiff (ml/min/1.73 m2) | ||||||
| Per SD increase | 0.894 (0.867–0.922) | <0.001 | 0.904 (0.872–0.937) | <0.001 | 0.909 (0.877–0.942) | <0.001 |
| Per SD increase (adjusted for eGFRcr) | 0.894 (0.866–0.923) | <0.001 | 0.885 (0.852–0.919) | <0.001 | 0.889 (0.856–0.923) | <0.001 |
| Categorical eGRFdiff (ml/min/1.73 m2) | ||||||
| Midrange (eGFRdiff −15–15) | Reference | Reference | Reference | |||
| Negative (eGFRdiff <−15) | 1.216 (1.144–1.293) | <0.001 | 1.216 (1.133–1.305) | <0.001 | 1.204 (1.121–1.292) | <0.001 |
| Positive (eGFRdiff ≥15) | 0.858 (0.745–0.988) | 0.035 | 0.933 (0.792–1.099) | 0.411 | 0.928 (0.787–1.093) | 0.373 |
| Cystatin C and creatinine-based kidney function measures | ||||||
| Continuous serum cystatin C (mg/l) | ||||||
| Per SD increase | 1.074 (1.040–1.110) | <0.001 | 1.121 (1.080–1.163) | <0.001 | 1.114 (1.074–1.156) | <0.001 |
| Per SD increase (adjusted for creatinine) | 1.120 (1.079–1.164) | <0.001 | 1.145 (1.099–1.194) | <0.001 | 1.138 (1.093–1.187) | <0.001 |
| Continuous eGFRcys (ml/min/1.73 m2) | ||||||
| Per SD increase | 0.913 (0.881–0.945) | <0.001 | 0.872 (0.837–0.908) | <0.001 | 0.874 (0.840–0.910) | <0.001 |
| Per SD increase (adjusted for eGFRcr) | 0.873 (0.840–0.908) | <0.001 | 0.862 (0.824–0.902) | <0.001 | 0.868 (0.829–0.908) | <0.001 |
| Continuous serum creatinine (mg/dl) | ||||||
| Per SD increase | 0.946 (0.911–0.983) | 0.004 | 1.007 (0.965–1.051) | 0.749 | 1.024 (0.985–1.065) | 0.235 |
| Per SD increase (adjusted for cystatin C) | 0.896 (0.859–0.934) | <0.001 | 0.942 (0.898–0.988) | 0.013 | 0.956 (0.914–1.001) | 0.054 |
| Continuous eGFRcr (ml/min/1.73 m2) | ||||||
| Per SD increase | 1.067 (1.030–1.106) | <0.001 | 0.975 (0.935–1.016) | 0.228 | 0.969 (0.930–1.010) | 0.141 |
| Per SD increase (adjusted for eGFRcys) | 1.102 (1.060–1.146) | <0.001 | 1.024 (0.978–1.072) | 0.310 | 1.017 (0.972–1.065) | 0.466 |
| Continuous eGRFcys-cr (ml/min/1.73 m2) | ||||||
| Per SD increase | 0.979 (0.944–1.015) | 0.240 | 0.897 (0.86–0.935) | <0.001 | 0.896 (0.859–0.934) | <0.001 |
| Per SD increase (adjusted for eGFRcr) | 0.854 (0.809–0.901) | <0.001 | 0.819 (0.769–0.871) | <0.001 | 0.824 (0.774–0.878) | <0.001 |
| Per SD increase (adjusted for eGFRcys) | 1.333 (1.216–1.462) | <0.001 | 1.052 (0.945–1.171) | 0.356 | 1.035 (0.930–1.153) | 0.527 |
Model 1: adjusted for age, gender, marital status, education level, residence, smoking status, drinking status, depressive symptoms, BMI, restriction on ADL, hypertension, diabetes, stroke, heart disease, chronic lung disease, cancer, total cholesterol, hs-CRP, use of antihypertensive agents and medication history of kidney disease. Model 2: further adjusted for global cognitive scores at baseline in 2011. Model 3: further adjusted for muscle strength assessed by grip strength (normalized by body weight).
Significant values in bold.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
